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A b s T r A C T
Aim: Most patients treated for H. pylori infection 
receive empirical therapy based on epidemiological data 
of antibiotic resistance. however, previous European 
studies indicate that resistance patterns may be changing. 
Therefore, the aim of this study was to investigate the 
prevalence of primary clarithromycin and/or metronidazole-
resistant H. pylori strains over a six-year period (1997-2002) 
in a regional hospital.
Methods: All patients visiting slingeland hospital in 
doetinchem, the Netherlands between 1997 and 2002 
with a positive H. pylori culture were included in this study. 
susceptibility to metronidazole and clarithromycin was 
determined by disk diffusion.
results: of the 1355 patients with an H. pylori positive 
culture, 1127 did not have a history of H. pylori eradication, 
58 did, and for 170 this information was not available. 
Mean rates of primary resistance to metronidazole and 
clarithromycin were 14.4% (162/1125) and 1.0% (11/1123), 
respectively. primary metronidazole resistance was stable 
throughout the study period and primary clarithromycin 
resistance showed a decreasing trend. patients of foreign 
descent and from secondary care had a higher chance of 
harbouring primary metronidazole-resistant H. pylori 
(adjusted or (95% Ci) 1.75 (1.1 to 2.8), and 1.60 (1.1 to 2.2), 
respectively). patients with failed H. pylori eradication had 
a higher chance of harbouring metronidazole-resistant 
H. pylori (43 vs 14%, p<0.0001) and clarithromycin-resistant 
H. pylori (5.3 vs 1.0%, p=0.004) than untreated patients.
Conclusion: primary metronidazole resistance is stable 
at a low level, while primary clarithromycin resistance is 
virtually absent in the eastern part of the Netherlands. 
Therefore, triple therapy with a proton pump inhibitor, 
clarithromycin and amoxicillin can remain the empirical 
treatment of choice in the Netherlands.
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i N T r o d u C T i o N
During the past decade it has been established that not 
only patients with peptic ulcer disease but also a subgroup 
of patients with functional dyspepsia benefit from 
Helicobacter pylori eradication.1,2 Therefore, H. pylori test-
and-eradication has been incorporated in most guidelines 
for treatment of primary care patients with dyspeptic 
symptoms.3-5 As a result, many patients now receive therapy 
for H. pylori infection.
Several therapy regimens are effective for treatment of 
this infection, but the current European guidelines as 
well as the Dutch guidelines recommend triple therapy 
based on a proton pump inhibitor or ranitidine bismuth 
citrate, combined with two antibiotics (clarithromycin and 
amoxicillin or metronidazole) as first-line treatment.3-5 
These regimens reach high cure rates in clinical trials.6 
However, cure rates are substantially lower in case of 
resistance to the antibiotics used.7-9
H. pylori can be (or become) resistant to clarithromycin 
and metronidazole and ideally therapy should be based 
on culture results. However, with the new noninvasive 
management strategies, fewer patients have upper 
gastrointestinal endoscopy.10 Even if endoscopy is 
performed, taking biopsies for culture is often omitted 
because of the high cost. Therefore culture-based 
antimicrobial susceptibility data are not generally available 
in routine clinical practice. Thus, the choice of therapy 
is usually based on epidemiological data of the local 
prevalence of antibiotic-resistant H. pylori strains.
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However, the prevalence of antibiotic-resistant H. pylori 
strains may be changing. Van der Wouden et al.11 reported a 
rapid increase in metronidazole resistance in the northern 
part of the Netherlands. And several studies in other 
countries also showed increasing rates of both metronidazole 
and clarithromycin resistance.12-15 Therefore, in order to be 
able to decide which combination of antibiotics should be 
used for the treatment of H. pylori infection recent data 
on the local antibiotic resistance patterns are needed. 
Unfortunately there is only one recent Dutch study on this 
subject. This study by Loffeld et al.16 showed fairly stable 
rates of antibiotic resistance. But more research is necessary 
to confirm this for other parts of the Netherlands.
Therefore, the aim of this study was to evaluate the 
prevalence of both primary and secondary clarithromycin 
and/or metronidazole resistant H. pylori strains in the 
eastern part of the Netherlands and to monitor changes 
over a six-year period (1997-2002).
M E T h o d s
study population
All patients who underwent diagnostic upper 
gastrointestinal endoscopy in Slingeland Hospital in 
Doetinchem, the Netherlands, between 1 January 1997 
and 31 December 2002, and who had a culture positive 
for H. pylori were included in this study. Data regarding 
antibiotic susceptibility, gender, age, country of origin, 
referring physician (primary or secondary care), and 
previous (failed) H. pylori eradication were entered into a 
database.
H. pylori culture and antibiotic susceptibility testing
H. pylori was cultured from one gastric biopsy specimen 
(antrum or corpus) on chocolate agar and a Skirrow 
plate (Regional Laboratory Arnhem, the Netherlands). 
Plates were incubated in a micro-aerobic atmosphere at 
37°C and examined after three, seven ands ten days of 
incubation. H. pylori was identified by colony appearance, 
Gram staining and positive biochemical tests (catalase, 
oxidase and urease).
Susceptibility to metronidazole and clarithromycin was 
determined by disk diffusion: a 16 mg metronidazole disk 
and a 30 mg clarithromycin disk were placed on separate 
chocolate agar plates with three to five suspected colonies 
of H. pylori. Plates were incubated in a microaerophilic 
atmosphere at 37°C for 72 hours. Antibiotic susceptibility 
was determined by measuring the growth inhibition 
zone around the disk. Strains were considered resistant 
to clarithromycin when the growth inhibition zone was 
<19 mm and to metronidazole when it was <23 mm.17
data analysis
Primary outcome was the prevalence of resistance to 
metronidazole or clarithromycin. Baseline characteristics 
of patients harbouring antibiotic resistant and susceptible 
strains were compared using the 2 test. Baseline 
characteristics and study year were related to the presence 
of antibiotic resistance using unadjusted and adjusted 
logistic regression analyses. Data were analysed using SAS 
software (SAS Institute Inc., USA). Statistical significance 




During the study period 1355 patients had a culture 
positive for H. pylori. Fifty-eight of these patients had 
had a previously failed attempt to eradicate H. pylori, for 
170 there were no data available regarding prior H. pylori 











- Male 54 (520) 49 (79) 53 (594) 36 (4)
- Female 46 (442) 51 (83) 47 (517) 64 (7)
Age in years: mean (SD) 55 (16) 56 (17) 55 (16) 60 (20)
Descent
- Dutch 86 (822) 80 (130) 85 (939) 91 (10)
- Foreign 14 (135) 20 (32) 15 (167) 9 (1)
Referring physician*
Primary 64 (602) 52 (82) 62 (676) 50 (5)
Secondary 36 (345) 48 (76) 38 (417) 50 (5)
*p<0.05 for the difference between metronidazole susceptible and resistant strains.
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eradication. The remaining 1127 patients who did not have 
a history of H. pylori eradication were studied for primary 
metronidazole and clarithromycin resistance. Table 1 shows 
the baseline characteristics of these patients related to the 
presence of primary metronidazole and clarithromycin 
resistance.
prevalence of antibiotic resistance 
Metronidazole susceptibility was successfully tested in 
1125 patients and resistance was found in 162 (14.4%, 
95% CI 12.3 to 16.5%) of these patients. Clarithromycin 
susceptibility was successfully tested in 1123 patients and 
resistance was found in 11 (1.0%, 95% CI 0.4 to 1.6%) of 
these patients.
Figure 1 shows that the prevalence of metronidazole 
resistance was fairly stable during the study period (odds 
ratio for study year 0.96 (95% CI 0.9 to 1.1)). Furthermore, 
figure 1 shows that the prevalence of clarithromycin 
resistance decreased during the study period (odds ratio for 
study year 0.58 (95% CI 0.40 to 0.9)), although this result 
is difficult to interpret due to the low number of patients 
with clarithromycin-resistant strains.
factors associated with primary antibiotic resistance
Table 2 shows that patients of foreign descent and patients 
referred by a secondary care physician were more likely to 
harbour metronidazole-resistant strains. It was not feasible 
to perform these analyses for clarithromycin resistance 
due to the very low number of clarithromycin-resistant 
H. pylori strains.
secondary antibiotic resistance
Prevalence of both metronidazole and clarithromycin 
resistance was higher in the 58 patients with a previous 
(failed) attempt to eradicate H. pylori than in previously 
untreated patients (metronidazole: 43 vs 14% p<0.0001 and 
clarithromycin: 5.3 vs 1.0% p=0.004, respectively).
d i s C u s s i o N
Because most patients are treated for H. pylori without 
prior susceptibility testing it is important to gather 
epidemiological data on the current prevalence of antibiotic 
resistance to guide empirical therapy, which was the 
aim of this study. The present study shows that primary 
metronidazole resistance was stable throughout the study 
period (1997 to 2002) with a mean prevalence of 14%. 
Furthermore, the results show that the prevalence of 
primary clarithromycin resistance was very low (mean 
prevalence 1%) and showed a decreasing trend.
Our figures are somewhat lower than those recently 
reported by Loffeld et al.16 for 976 H. pylori positive 
cultures from another Dutch region (26% primary 
metronidazole resistance and 5% primary clarithromycin 
resistance). This can partly be explained by the higher 
proportion of patients of Mediterranean descent (who have 
a higher prevalence of antibiotic resistance) in the study 
by Loffeld et al. However, our results are comparable with 
data from other Dutch regions, published as abstracts only. 
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figure 1. Proportions of primary metronidazole 




















Table 2. Factors associated with primary metronidazole resistance
factor unadjusted analysis
odds ratio (95% Ci)
Adjusted analysis
odds ratio (95% Ci)
Age group (old vs young) 1.11 (0.8-1.6) 1.23 (0.8-1.8)
Gender (female vs male) 1.24 (0.9-1.7) 1.22 (0.9-1.7)
Descent (foreign vs Dutch) 1.50 (1.0-2.2) 1.75 (1.1-2.8)*
Referring physician (secondary vs primary care) 1.62 (1.2-2.3)* 1.60 (1.1-2.2)*
Year of the study period 0.96 (0.9-1.1) 0.93 (0.8-1.1)
*p<0.05.
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Arents et al.18 studied 6648 H. pylori positive cultures 
in the north of the Netherlands and found that primary 
metronidazole resistance had decreased from 28% in 1996 
to 13% in 2001, and that clarithromycin resistance ranged 
from 1 to 3% without evident trends. Moreover, Janssen 
et al.19 found a 14% metronidazole resistance and a 3% 
clarithromycin resistance when studying 961 H. pylori 
positive cultures in the south of the Netherlands.
Our results do not confirm the rapid increase in 
metronidazole resistance (from 7% in 1993 to 32% in 
1996) as reported by Van der Wouden et al.11 for 1037 
isolates from the north of the Netherlands. However, more 
recent data from that area did not confirm this increase; in 
fact they showed that this increase turned into a decrease 
after 1996.18
Compared with other European countries both primary 
metronidazole resistance and primary clarithromycin 
resistance are low in the Netherlands.12-14,20,21 These 
differences in primary antibiotic resistance may be related to 
the use of antibiotics for other indications. In the Netherlands 
sales of antibiotics are lower than in any other country of the 
European Union. In fact, in France, Spain, Italy and Greece 
sales of macrolide antibiotics are about four times higher than 
in the Netherlands and this may explain the higher prevalence 
of clarithromycin resistance in these countries.22-24
Our results showed that patients originating from foreign 
countries (nearly all from Turkey) were more likely to harbour 
strains resistant to metronidazole than patients of Dutch 
descent. This has been confirmed by other research16 and it 
probably reflects the higher frequency of metronidazole use 
for other indications in these countries. Furthermore, both 
metronidazole and clarithromycin resistance were about 
four times higher in patients with a history of failed H. 
pylori eradication than in untreated patients. This reflects 
the induction of secondary resistance to metronidazole 
and/or clarithromycin depending on the antibiotics used in 
the failed H. pylori eradication. Therefore, it is important to 
take a thorough medical history regarding previous failed H. 
pylori treatments in order to determine which antibiotics can 
be used for a subsequent attempt to eradicate H. pylori.
In this study H. pylori susceptibility was tested using 
disk diffusion. Although agar dilution is considered the 
gold standard, this method is too demanding for everyday 
practice and it can be replaced by E-test or disk diffusion. 
Initially E-test was considered superior to disk diffusion, 
but several studies show that both methods produce 
comparable results. In comparison with agar dilution both 
methods are hampered with some discordant results for 
metronidazole susceptibility, especially in the intermediate 
susceptibility range.25-27
Based on our results it should be advised to use clarithromycin-
based triple therapy rather than metronidazole-based 
triple therapy for empirical first-line treatment of H. pylori 
infections in our region. Triple therapy with clarithromycin 
and amoxicillin is the treatment of choice because it is not 
hampered by metronidazole resistance28 and because this 
regimen cannot induce double antibiotic resistance (to both 
clarithromycin and metronidazole).29,30 Therefore, failure of 
this therapy still leaves the option of empirical second-line 
therapy based on metronidazole, preferably quadruple therapy 
since this therapy may overcome metronidazole resistance.9,30 
Regarding the low prevalence of primary antibiotic resistance, 
culture and susceptibility testing are not necessary for this 
combination of first-line and second-line therapy.
In conclusion, in the eastern part of the Netherlands, 
primary metronidazole resistance was stable at a low level, 
while primary clarithromycin resistance was virtually absent. 
Therefore, triple therapy with clarithromycin and amoxicillin 
can remain the empirical treatment of choice in this area.
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